By Dean Seal


Virax Biolabs Group Ltd. has received emergency use authorization from the Food and Drug Administration for its over-the-counter Covid-19 rapid antigen test.

Chief Executive James Foster said Tuesday that the authorization allows the company to enter the U.S. market and that Virax has manufacturing capacity, through a partner, for up to 2 million tests a day.

Tests are ready for sale in the U.S., the biotech company said, noting it is also seeking approval for another rapid antigen test to be distributed in Canada.


Write to Dean Seal at


(END) Dow Jones Newswires

December 06, 2022 08:25 ET (13:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.